Format

Send to:

Choose Destination
See comment in PubMed Commons below
J Allergy Clin Immunol. 2014 Jan;133(1):121-9.e1-2. doi: 10.1016/j.jaci.2013.05.032. Epub 2013 Jul 16.

Efficacy of a short course of specific immunotherapy in patients with allergic rhinoconjunctivitis to ragweed pollen.

Author information

  • 1Allied Research International, Mississauga, Ontario, Canada. Electronic address: PPatel@inflamaxresearch.com.
  • 2Allergy Therapeutics, West Sussex, United Kingdom.
  • 3Bencard Allergie, Munich, Germany.

Abstract

BACKGROUND:

Specific immunotherapy acts to modify the underlying cause of allergic rhinoconjunctivitis. Addition of adjuvants, such as monophosphoryl lipid A (MPL), might allow for efficacious and safe treatment with only 4 injections administered preseasonally, which is in contrast to most available schedules requiring long injection courses.

OBJECTIVE:

The primary objective was to assess the clinical efficacy of Ragweed MATA MPL (short ragweed pollen allergoid adsorbed to L-Tyrosine + MPL) versus placebo in reducing allergic rhinoconjunctivitis symptoms caused by ragweed pollen in an environmental exposure chamber (EEC) 3 weeks after treatment.

METHODS:

This was a randomized, double-blind, placebo-controlled phase IIb study to evaluate the clinical efficacy and safety of Ragweed MATA MPL compared with placebo by using controlled ragweed pollen exposure in an EEC. Two hundred twenty-eight patients with a history of ragweed allergy and positive skin prick test responses to ragweed were randomized and received 4 weekly injections of active treatment or placebo. Total nasal and nonnasal symptom scores were obtained in the EEC before and after treatment.

RESULTS:

Mean improvement in total symptom scores in the Ragweed MATA MPL group was statistically significantly greater than in the placebo group (relative mean improvement of active vs placebo, 48%; P < .05; median improvement, 82%). The majority of adverse events (AEs) experienced by subjects were mild injection-site reactions. No severe systemic AEs or serious AEs occurred during the study.

CONCLUSION:

This study demonstrated that an ultrashort course of Ragweed MATA MPL is efficacious in reducing allergy symptoms in patients with seasonal allergic rhinitis and that it is well tolerated.

Copyright © 2013 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved.

KEYWORDS:

AE; AR; Adverse event; Allergic rhinoconjunctivitis; EEC; Environmental exposure chamber; ITT; Intention to treat; MPL; Monophosphoryl lipid A; PP; Per protocol; RQLQ; Rhinoconjunctivitis Quality of Life Questionnaire; SAR; SIT; SU; Seasonal allergic rhinitis; Specific immunotherapy; Standardized units; TSS; Total symptom score; environmental exposure chamber; ragweed; specific immunotherapy; ultrashort course

PMID:
23870670
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk